Tan, Xi
Liang, Yuanjie
Rajpura, Jigar R.
Yedigarova, Larisa
Noone, Josh
Xie, Lin
Inzucchi, Silvio
de Havenon, Adam
Article History
Received: 27 September 2023
Accepted: 3 November 2023
First Online: 20 November 2023
Declarations
:
: As this study used only de-identified patient records and did not involve the collection, use or transmittal of individually identifiable data, institutional review board approval was not required.
: XT, YL, JRR, LY, JN, and LX are employed by Novo Nordisk Inc. LX has been employed by Pfizer within the last 3 years. SI reports honorarium for consulting and/or clinical trial committee work from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Merck, Pfizer, and Bayer. He has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. AdH reports NIH/NINDS funding (K23NS105924, R01NS130189, UG3NS130228). AdH has received investigator-initiated clinical research funding from the AAN, has received consultant fees from Integra and Novo Nordisk, has received royalty fees from UpToDate, and has equity in Titin KM and Certus. The study findings have been presented at the American Diabetes Association 83rd Scientific Sessions 2023 and at the International Conference on Pharmacoepidemiology (ICPE) 2023.